North America Sexually Transmitted Diseases (STD) Testing Market Size, Share & Industry Trends Analysis Report By Disease Type, By the Location of Testing, By Country, Historical Data and Growth Forecast, 2021 - 2027
Get in-depth analysis of the COVID-19 impact on the North America Sexually Transmitted Diseases (STD) Testing Market
Market Report Description
The North America Sexually Transmitted Diseases (STD) Testing Market would witness market growth of 4.3% CAGR during the forecast period (2021-2027).
The prevalence of sexually transmitted diseases has increased as a result of a surge in unprotected intercourse, which would fuel the need for sexually transmitted disease testing globally. Even if a person has no symptoms but has had unprotected sex, doctors will usually recommend STD testing. Viral load monitoring, genotyping, immunoassays, and molecular diagnostics are some of the STD diagnostics available in the market.
Simultaneous testing for many targets is one way to improve testing reliability. Compensating for genotype changes, mutations, and mismatches have boosted the probability of detection for infections such as HIV, syphilis, hepatitis C virus (HCV), and chlamydia, and can help to detect cases of co-infection in advance.
According to CDC, in 2019, 2.5 million cases of gonorrhoea, chlamydia, and syphilis, which are the three most common STDs, were reported in the US. Between 2015 and 2019, there was an almost 30% increase in these reportable STDs. Owing to this rising prevalence of STDs in the US and other developed nations and the growing initiatives to aware people regarding STDs, the demand for STD testing would increase in the coming years. For instance, programs initiated by CDC stated that innovative STD testing procedures are crucial for STD prevention. STD care is growing beyond the clinic environment, with new options for phone, video, and online health care appointments. Expanding these measures can assist authorities in reducing STDs and addressing previously unresolved health-care access issues.
The US market dominated the North America Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $25.63 billion by 2027. The Canada market is poised to grow at a CAGR of 6.6% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 5.7% during (2021 - 2027).
Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type
- Herpes simplex
- Human papillomavirus (HPV)
- Other Disease
By Location of Testing
- Laboratory Testing
- Point of care (POC) Testing
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- BioMérieux S.A.
- Abbott Laboratories
- Becton, Dickinson and Company
- Hologic, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- DiaSorin Molecular LLC
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- OraSure Technologies, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free